BioMed Research International / 2020 / Article / Tab 3

Review Article

miR-19 Is a Potential Clinical Biomarker for Gastrointestinal Malignancy: A Systematic Review and Meta-analysis

Table 3

Subgroup analyses were stratified on the basis of histology.

StageGradeLymph node metastasisDistant metastasis

Colorectal cancerOR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)
62.74 (1.45, 5.18)31.36 (0.74, 2.51)71.89 (0.99, 3.63)82.02 (0.77, 5.32)
Gastric cancerOR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)
20.42 (0.17, 1.04)20.31 (0.14, 0.70)30.46 (0.14, 1.52)10.31 (0.10, 0.97)
Esophagus cancerOR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)
11.72 (0.95, 3.12)11.65 (0.86, 3.16)11.87 (0.91, 3.85)NoneNone
Liver cancerOR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)
40.66 (0.18, 2.45)40.80 (0.47, 1.35)14.75 (1.37, 16.47)NoneNone
Pancreatic cancerOR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)
NoneNoneNoneNoneNoneNoneNoneNone

Abbreviations: : study numbers.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.